VAMP1
Basic information
Region (hg38): 12:6462237-6470677
Previous symbols: [ "SYB1" ]
Links
Phenotypes
GenCC
Source:
- myasthenic syndrome, congenital, 25, presynaptic (Strong), mode of inheritance: AR
- myasthenic syndrome, congenital, 25, presynaptic (Strong), mode of inheritance: AR
- presynaptic congenital myasthenic syndrome (Supportive), mode of inheritance: AD
- spastic ataxia 1 (Supportive), mode of inheritance: AD
- myasthenic syndrome, congenital, 25, presynaptic (Strong), mode of inheritance: AR
- spastic ataxia 1 (Strong), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Myasthenic syndrome, congenital, 25, presynaptic | AR | Musculoskeletal; Neurologic | The condition can involve neonatal hypotonia and generalized muscle weakness, and medicial management (with pyridostigmine) has been described as beneficial | Musculoskeletal; Neurologic | 11774073; 22958904; 28168212; 28253535; 28600779 |
ClinVar
This is a list of variants' phenotypes submitted to
- Spastic paraplegia (5 variants)
- not provided (3 variants)
- Spastic ataxia 1 (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the VAMP1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 10 | 12 | ||||
missense | 29 | 34 | ||||
nonsense | 2 | |||||
start loss | 0 | |||||
frameshift | 6 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 2 | 2 | 4 | |||
non coding | 20 | 14 | 37 | |||
Total | 5 | 3 | 35 | 33 | 15 |
Variants in VAMP1
This is a list of pathogenic ClinVar variants found in the VAMP1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
12-6462840-G-A | Benign/Likely benign (Jan 01, 2024) | |||
12-6462882-A-G | Myasthenic syndrome, congenital, 25, presynaptic • Spastic ataxia 1 | Benign (Dec 05, 2021) | ||
12-6463025-T-C | Benign (May 15, 2021) | |||
12-6464474-G-A | Spastic paraplegia | Uncertain significance (Aug 22, 2022) | ||
12-6464476-A-G | Spastic paraplegia | Likely benign (Aug 16, 2022) | ||
12-6464481-A-G | Spastic paraplegia | Uncertain significance (Dec 09, 2022) | ||
12-6464486-A-G | Spastic paraplegia | Uncertain significance (Nov 06, 2021) | ||
12-6464488-T-C | Myasthenic syndrome, congenital, 25, presynaptic • Spastic paraplegia | Uncertain significance (Sep 08, 2023) | ||
12-6464496-G-A | Spastic paraplegia | Likely benign (Oct 05, 2023) | ||
12-6464501-CAGG-C | Spastic paraplegia | Likely benign (Jan 03, 2023) | ||
12-6464504-G-T | Spastic paraplegia | Uncertain significance (Sep 19, 2023) | ||
12-6464505-A-C | Spastic paraplegia | Likely benign (Nov 28, 2023) | ||
12-6464505-AAG-TTT | Spastic paraplegia | Likely benign (Jan 03, 2023) | ||
12-6464510-C-T | Myasthenic syndrome, congenital, 25, presynaptic | Likely pathogenic (Jun 01, 2022) | ||
12-6464550-T-C | Benign (May 15, 2021) | |||
12-6464551-G-A | Benign (May 25, 2021) | |||
12-6464583-C-T | Benign (May 15, 2021) | |||
12-6464690-G-T | Benign (May 15, 2021) | |||
12-6464744-C-T | Benign (May 25, 2021) | |||
12-6464870-G-A | Spastic paraplegia | Likely benign (Nov 27, 2023) | ||
12-6464874-C-T | Spastic paraplegia | Likely benign (Nov 01, 2022) | ||
12-6464878-A-C | Spastic paraplegia | Likely benign (Mar 28, 2022) | ||
12-6464880-C-T | Spastic paraplegia | Likely benign (Jun 20, 2022) | ||
12-6464881-G-A | Spastic paraplegia | Likely benign (May 13, 2023) | ||
12-6464888-A-C | Spastic ataxia 1 • Spastic paraplegia | Pathogenic (Jun 10, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
VAMP1 | protein_coding | protein_coding | ENST00000396308 | 5 | 8751 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00394 | 0.867 | 125737 | 0 | 11 | 125748 | 0.0000437 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 1.23 | 38 | 66.3 | 0.573 | 0.00000332 | 764 |
Missense in Polyphen | 10 | 16.869 | 0.5928 | 222 | ||
Synonymous | 0.471 | 20 | 22.9 | 0.875 | 0.00000112 | 233 |
Loss of Function | 1.28 | 5 | 9.18 | 0.545 | 5.76e-7 | 87 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.0000578 | 0.0000578 |
Ashkenazi Jewish | 0.0000992 | 0.0000992 |
East Asian | 0.000109 | 0.000109 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000440 | 0.0000439 |
Middle Eastern | 0.000109 | 0.000109 |
South Asian | 0.0000327 | 0.0000327 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Involved in the targeting and/or fusion of transport vesicles to their target membrane.;
- Disease
- DISEASE: Spastic ataxia 1, autosomal dominant (SPAX1) [MIM:108600]: An autosomal dominant form of spastic ataxia, a progressive neurodegenerative disorder characterized by lower-limb spasticity and generalized ataxia with dysarthria, impaired ocular movements, and gait disturbance. {ECO:0000269|PubMed:22958904}. Note=The disease is caused by mutations affecting the gene represented in this entry. A mutation affecting a critical donor site for the splicing of VAMP1 isoforms leads to the loss of neuron-specific isoform 1 and subsequently results in haploinsufficiency (PubMed:22958904). Therefore, there would be less neurotransmitter exocytosis in specific regions of the brain, causing the symptoms of SPAX1. {ECO:0000303|PubMed:22958904}.;
- Pathway
- SNARE interactions in vesicular transport - Homo sapiens (human);Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics;Disease;Toxicity of botulinum toxin type D (BoNT/D);Toxicity of botulinum toxin type F (BoNT/F);Uptake and actions of bacterial toxins;Toxicity of botulinum toxin type G (BoNT/G);Neurotoxicity of clostridium toxins;Infectious disease
(Consensus)
Recessive Scores
- pRec
- 0.137
Intolerance Scores
- loftool
- rvis_EVS
- 0.24
- rvis_percentile_EVS
- 68.72
Haploinsufficiency Scores
- pHI
- 0.174
- hipred
- Y
- hipred_score
- 0.514
- ghis
- 0.552
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.815
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Low | Medium |
Primary Immunodeficiency | Medium | Low | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Vamp1
- Phenotype
- growth/size/body region phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan);
Gene ontology
- Biological process
- synaptic vesicle priming;regulation of synaptic vesicle fusion to presynaptic active zone membrane;SNARE complex assembly
- Cellular component
- mitochondrial outer membrane;cytosol;integral component of plasma membrane;cell surface;cell junction;integral component of synaptic vesicle membrane;synaptic vesicle membrane;neuromuscular junction;azurophil granule membrane;specific granule membrane;neuron projection;tertiary granule membrane;glutamatergic synapse
- Molecular function
- protein binding